节点文献

秋水仙碱治疗新型冠状病毒肺炎研究

Colchicine in the treatment of coronavirus disease 2019

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 曹灵赵天仪朱小霞邹和建

【Author】 CAO Ling;ZHAO Tianyi;ZHU Xiaoxia;ZOU Hejian;Department of Rheumatology, Huashan Hospital, Fudan University;Institute of Rheumatology, Immunology and Allergy, Fudan University;

【通讯作者】 邹和建;

【机构】 复旦大学附属华山医院风湿免疫科复旦大学风湿免疫过敏性疾病研究中心

【摘要】 新型冠状病毒肺炎(coronavirus disease 2019, COVID-19)仍在全球肆虐,对其患者除对症处理外,没有有效的治疗措施。目前,COVID-19治疗以抗病毒治疗为主,酌情给予抗炎治疗,但除糖皮质激素外,其他抗炎药物的使用并无明确的依据。秋水仙碱是临床上常用的抗炎药物之一,有研究发现它治疗COVID-19有效,现正在进行多项临床研究。本文介绍秋水仙碱治疗COVID-19有效的可能机制和相关临床研究情况。

【Abstract】 Coronavirus disease 2019(COVID-19) is still raging around the world and there is no effective therapy for its patients except for the symptomatic treatment. At present, the treatment of COVID-19 is based on antiviral therapy and antiinflammatory treatment is given as appropriate. However, there is no clear basis for the use of other anti-inflammatory drugs except for glucocorticoids. Colchicine is one of the anti-inflammatory drugs commonly used in clinic, studies have found that it is effective in the treatment of COVID-19 and a number of clinical trials are currently underway. This article introduces the possible mechanisms of colchicine for the effective treatment of COVID-19 and the related clinical research status.

【关键词】 秋水仙碱新型冠状病毒肺炎临床研究
【Key words】 colchicineCOVID-19clinical study
【基金】 上海申康医院发展中心专科疾病临床“五新”转化项目(16CR3012A);上海申康医院发展中心适宜技术联合开发推广应用项目(SHDC12016227)
  • 【文献出处】 上海医药 ,Shanghai Medical & Pharmaceutical Journal , 编辑部邮箱 ,2021年19期
  • 【分类号】R563.1
  • 【下载频次】233
节点文献中: 

本文链接的文献网络图示:

本文的引文网络